Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.28 |
---|---|
High | 2.30 |
Low | 1.76 |
Bid | 1.87 |
Offer | 1.90 |
Previous close | 2.26 |
Average volume | 2.28m |
---|---|
Shares outstanding | 48.85m |
Free float | 47.34m |
P/E (TTM) | -- |
Market cap | 91.35m USD |
EPS (TTM) | -2.17 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 20:59 GMT.
More ▼
- Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
- Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
- Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
- Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
- Cabaletta Bio to Participate in Upcoming Investor Conferences in September
- Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
- Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
- Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
- Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
- Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
More ▼